PF-04634817

DRUG6 trials

Sponsors

Pfizer

Conditions

Diabetic NephropathyHealthyMacular Edema, DiabeticRenal Insufficiency

Phase 1

First In Human Study Of Increasing Oral Doses Of PF-04634817

CompletedNCT01098877

Start: 2010-04-30End: 2010-09-30Updated: 2010-10-13

A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects

CompletedNCT01140672

Start: 2010-06-30End: 2010-10-31Updated: 2011-06-08

A Comparison Of A Single PF-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers

CompletedNCT01247883

Start: 2010-10-31End: 2010-12-31Updated: 2011-02-02

PF-04634817 Renal Impairment Study

CompletedNCT01791855

PfizerRenal Insufficiency

Start: 2013-05-10End: 2013-09-03Updated: 2024-03-01

Phase 2

A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy

CompletedNCT01712061

PfizerDiabetic Nephropathy

Start: 2012-12-31End: 2014-09-30Updated: 2015-10-21

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

TerminatedNCT01994291

PfizerMacular Edema, Diabetic

Start: 2013-11-30End: 2015-08-31Updated: 2016-10-17